Late-onset toxicities of monoclonal antibodies in cancer patients

Mai Alalawi, Abrar Saeed Bakr, Rowaida Reda, Karim Thomas Sadak, Mohamad Nagy

Research output: Contribution to journalReview articlepeer-review

2 Scopus citations


Cancer therapy duration is variable and may take years, adding a new challenge of maintaining the best life quality for cancer survivors. In cancer patients, late-onset toxicities have been reported with monoclonal antibodies and may involve several body organs or systems. They are defined as an autoimmune illnesses that can happen months to years after treatment discontinuation. Late-onset toxicities have become a focus of clinical care and related research. After cancer therapy is completed, the patient should receive longitudinal follow-up to detect these late effects as early as possible. The current review summarizes the recently reported late-onset toxicities of four classes of monoclonal antibodies (anti-CD52, anti-CTLA-4, anti-PD-1 and anti-CD20) with guidance for the diagnostic tools, appropriate management and treatment.

Original languageEnglish (US)
Pages (from-to)1067-1083
Number of pages17
Issue number13
StatePublished - Sep 2022

Bibliographical note

Funding Information:
The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants, or patents received or pending, or royalties.

Publisher Copyright:
© 2022 Future Medicine Ltd.


  • anti-CD20
  • anti-CD52
  • anti-CTLA-4
  • delayed immune-related event
  • immune checkpoints inhibitors
  • late-onset toxicity
  • monoclonal antibodies

PubMed: MeSH publication types

  • Journal Article
  • Review


Dive into the research topics of 'Late-onset toxicities of monoclonal antibodies in cancer patients'. Together they form a unique fingerprint.

Cite this